{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T06:08:29Z","timestamp":1749794909768},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin. J. Integr. Med."],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11655-023-3705-1","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:02:41Z","timestamp":1699545761000},"page":"339-347","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway"],"prefix":"10.1007","volume":"30","author":[{"given":"Hua-feng","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-qiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-jun","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He-fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-qing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mou-chun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"3705_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016;150:835\u2013853.","journal-title":"Gastroenterology"},{"key":"3705_CR2","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1200\/JCO.2014.60.1153","volume":"33","author":"JJ Knox","year":"2015","unstructured":"Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol 2015;33:1835\u20131844.","journal-title":"J Clin Oncol"},{"key":"3705_CR3","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.3390\/cancers14112798","volume":"14","author":"E Chakraborty","year":"2022","unstructured":"Chakraborty E, Sarkar D. Emerging therapies for hepatocellular carcinoma (HCC). Cancers (Basel) 2022;14:2798.","journal-title":"Cancers (Basel)"},{"key":"3705_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","volume":"13","author":"T Couri","year":"2019","unstructured":"Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int 2019;13:125\u2013137.","journal-title":"Hepatol Int"},{"key":"3705_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3892\/ol.2021.12540","volume":"21","author":"J Wang","year":"2021","unstructured":"Wang J, Li J, Tang G, Tian Y, Su S, Li Y. Clinical outcomes and influencing factors of PD-1\/PD-L1 in hepatocellular carcinoma. Oncol Lett 2021;21:279.","journal-title":"Oncol Lett"},{"key":"3705_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974\u20131982.","journal-title":"J Clin Oncol"},{"key":"3705_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450\u2013461.","journal-title":"Cancer Cell"},{"key":"3705_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther 2015;146:132\u2013149.","journal-title":"Pharmacol Ther"},{"key":"3705_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/jcm8010038","volume":"8","author":"MR Pan","year":"2019","unstructured":"Pan MR, Hou MF, Ou-Yang F, Wu CC, Chang SJ, Hung WC, et al. FAK is required for tumor metastasis-related fluid microenvironment in triple-negative breast cancer. J Clin Med 2019;8:38.","journal-title":"J Clin Med"},{"key":"3705_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","volume":"163","author":"A Serrels","year":"2015","unstructured":"Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 2015;163:160\u2013173.","journal-title":"Cell"},{"key":"3705_CR11","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/erm.2018.3","volume":"20","author":"J Wang","year":"2018","unstructured":"Wang J, Wong YK, Liao F. What has traditional Chinese medicine delivered for modern medicine? Expert Rev Mol Med 2018;20:e4.","journal-title":"Expert Rev Mol Med"},{"key":"3705_CR12","doi-asserted-by":"publisher","first-page":"6672","DOI":"10.19082\/6672","volume":"10","author":"E Delshad","year":"2018","unstructured":"Delshad E, Yousefi M, Sasannezhad P, Rakhshandeh H, Ayati Z. Medical uses of Carthamus tinctorius L. (Safflower): a comprehensive review from traditional medicine to modern medicine. Electron Physician 2018;10:6672\u20136681.","journal-title":"Electron Physician"},{"key":"3705_CR13","first-page":"2108557","volume":"2022","author":"Y Chen","year":"2022","unstructured":"Chen Y, Li MF, Wen JY, Pan XQ, Deng ZX, Chen JR, et al. Pharmacological activities of safflower yellow and its clinical applications. Evid Based Complement Alternat Med 2022;2022:2108557.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3705_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/ijmm.2016.2462","volume":"37","author":"Z Ma","year":"2016","unstructured":"Ma Z, Li C, Qiao Y, Lu C, Li J, Song W, et al. Safflower yellow B suppresses HepG2 cell injury induced by oxidative stress through the AKT\/Nrf2 pathway. Int J Mol Med 2016;37:603\u2013612.","journal-title":"Int J Mol Med"},{"key":"3705_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ctim.2014.01.001","volume":"22","author":"S Fan","year":"2014","unstructured":"Fan S, Lin N, Shan G, Zuo P, Cui L. Safflower yellow for acute ischemic stroke: a systematic review of randomized controlled trials. Complement Ther Med 2014;22:354\u2013361.","journal-title":"Complement Ther Med"},{"key":"3705_CR16","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1142\/S0192415X1650083X","volume":"44","author":"H Fu","year":"2016","unstructured":"Fu H, Wu R, Li Y, Zhang L, Tang X, Tu J, et al. Safflower yellow prevents pulmonary metastasis of breast cancer by inhibiting tumor cell invadopodia. Am J Chin Med 2016;44:1491\u20131506.","journal-title":"Am J Chin Med"},{"key":"3705_CR17","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1128\/JVI.78.8.4207-4223.2004","volume":"78","author":"N Sharma-Walia","year":"2004","unstructured":"Sharma-Walia N, Naranatt PP, Krishnan HH, Zeng L, Chandran B. Kaposi\u2019s sarcoma-associated herpesvirus\/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J Virol 2004;78:4207\u20134223.","journal-title":"J Virol"},{"key":"3705_CR18","doi-asserted-by":"publisher","first-page":"655697","DOI":"10.3389\/fimmu.2021.655697","volume":"12","author":"J Giraud","year":"2021","unstructured":"Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front Immunol 2021;12:655697.","journal-title":"Front Immunol"},{"key":"3705_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1159\/000457883","volume":"41","author":"W Ma","year":"2017","unstructured":"Ma W, Wu L, Zhou F, Hong Z, Yuan Y, Liu Z. T cell-associated immunotherapy for hepatocellular carcinoma. Cell Physiol Biochem 2017;41:609\u2013622.","journal-title":"Cell Physiol Biochem"},{"key":"3705_CR20","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.22.00972","volume":"41","author":"IMTSCTHWTCYB Sangro","year":"2023","unstructured":"Sangro IMTSCTHWTCYB. Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2023;41:1747\u20131757.","journal-title":"J Clin Oncol"},{"key":"3705_CR21","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci 2018;109:3993\u20134002.","journal-title":"Cancer Sci"},{"key":"3705_CR22","doi-asserted-by":"publisher","first-page":"10632","DOI":"10.1039\/D1FO01321A","volume":"12","author":"H Fu","year":"2021","unstructured":"Fu H, Liu X, Jin L, Lang J, Hu Z, Mao W, et al. Safflower yellow reduces DEN-induced hepatocellular carcinoma by enhancing liver immune infiltration through promotion of collagen degradation and modulation of gut microbiota. Food Funct 2021;12:10632\u201310643.","journal-title":"Food Funct"},{"key":"3705_CR23","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","volume":"22","author":"Y Lou","year":"2016","unstructured":"Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 2016;22:3630\u20133642.","journal-title":"Clin Cancer Res"},{"key":"3705_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","volume":"29","author":"H Tang","year":"2016","unstructured":"Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016;29:285\u2013296.","journal-title":"Cancer Cell"},{"key":"3705_CR25","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/0008-5472.CAN-15-1293","volume":"76","author":"DR Principe","year":"2016","unstructured":"Principe DR, DeCant B, Mascarinas E, Wayne EA, Diaz AM, Akagi N, et al. TGFbeta signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis. Cancer Res 2016;76:2525\u20132539.","journal-title":"Cancer Res"},{"key":"3705_CR26","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.3390\/pharmaceutics14122789","volume":"14","author":"DX Zhou","year":"2022","unstructured":"Zhou DX, Wang XH, Xu X, Chen WJ, Wei J, Chen TT, et al. Anti-tumor effects of engineered VNP20009-Abvec-Igkappa-mPD-1 strain in melanoma mice via combining the oncolytic therapy and immunotherapy. Pharmaceutics 2022;14:2789.","journal-title":"Pharmaceutics"},{"key":"3705_CR27","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, et al. Blocking IL-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci U S A 2019;116:1361\u20131369.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3705_CR28","doi-asserted-by":"publisher","first-page":"109746","DOI":"10.1016\/j.biopha.2019.109746","volume":"125","author":"J Wu","year":"2020","unstructured":"Wu J, Zhao X, Sun Q, Jiang Y, Zhang W, Luo J, et al. Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother 2020;125:109746.","journal-title":"Biomed Pharmacother"},{"key":"3705_CR29","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1186\/s12885-021-08974-3","volume":"21","author":"Y Sato","year":"2021","unstructured":"Sato Y, Fu Y, Liu H, Lee MY, Shaw MH. Tumor-immune profiling of CT-26 and colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer 2021;21:1222.","journal-title":"BMC Cancer"},{"key":"3705_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 2016;22:851\u2013860.","journal-title":"Nat Med"}],"container-title":["Chinese Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-023-3705-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11655-023-3705-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-023-3705-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T09:27:20Z","timestamp":1711099640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11655-023-3705-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3705"],"URL":"https:\/\/doi.org\/10.1007\/s11655-023-3705-1","relation":{},"ISSN":["1672-0415","1993-0402"],"issn-type":[{"value":"1672-0415","type":"print"},{"value":"1993-0402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"14 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}